Figure 2From: Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapyp-AKT (A; wildtype n = 41, mutant n = 24) and p-ERK (B; wildtype n = 42, mutant n = 23) expression by KRAS mutational status.Back to article page